APAC Consensus Recommendation on XLH – Multidisciplinary Management (Prof Craig F. Munns)

Part 5 – Special Population
SG-CRV-24-00011 APR2024

APAC Consensus Recommendation on XLH – Multidisciplinary Management (Prof Craig F. Munns)

Part 4 – Telemedicine
SG-CRV-24-00010 APR2024

APAC Consensus Recommendation on XLH – Multidisciplinary Management (Prof Craig F. Munns)

Part 3 – Multidisciplinary Management
SG-CRV-24-00009 APR2024

APAC Consensus Recommendation on XLH – Multidisciplinary Management (Prof Craig F. Munns)

Part 2 – Clinical Evidence of Burosumab & Other Clinical evidence
SG-CRV-24-00008 APR2024

APAC Consensus Recommendation on XLH – Multidisciplinary Management (Prof Craig F. Munns)

Part 1 – Management of XLH
SG-CRV-24-00007 MAR2024

APAC Consensus Recommendation on XLH – Screening and Diagnosis (Prof Manju Chandran)

MY-NP-24-00002 APR2024

APAC Consensus Recommendation on XLH – Multidisciplinary Management (Prof Craig F. Munns)

Full Video
MY-CRV-24-00001 MAR2024

APAC Consensus Recommendation on XLH – Transition of Care (Prof Rhee Yumie)

MY-NP-24-00001 MAR2024

ANZBMS 2023 Case Study – XLH – Management considerations in adulthood (Prof Rory Clifton-Bligh)

SG-CRV-24-00003 FEB2024

Key Clinical Questions about the diagnosis / treatment for XLH (Prof Craig F. Munns)

Full Video
MY-CRV-23-00049 JAN2024

Key Clinical Questions about the diagnosis / treatment for XLH (Prof Craig F. Munns)

Part 2 – Burosumab
MY-CRV-23-00047 JAN2024

An update on X-Linked Hypophosphatemia in Children and Adolescents (Prof Zulf Mughal)

MY-CRV-23-00046 JAN2024

An update on X-Linked Hypophosphatemia in Children and Adolescents (Prof Zulf Mughal)

MY-CRV-23-00050 JAN2024

Key Clinical Questions about the diagnosis / treatment for XLH (Prof Craig F. Munns)

Part 1 – Diagnosis/Treatment of XLH
MY-CRV-23-00047 JAN2024

ANZBMS2023 – The Australian Crysvita XLH Experience

MY-CRV-23-00045 DEC2023

APAC Consensus Recommendation on XLH – Screening and Diagnosis (Prof Manju Chandran)

Full Video
SG-NP-24-00004 MAR2024

Cameron’s story

The next chapter
KR315-2306CRV-V02

Case sharing by Prof. Thomas O. Carpenter : XLH – Management challenges during childhood & adolescence

Full Video
KR311-2306CRV-V01

Case sharing by Prof. Thomas O. Carpenter : XLH – Management challenges during childhood & adolescence

Questions & Answers
KR237-2212CRV-V02

Case sharing by Prof. Thomas O. Carpenter : XLH – Management challenges during childhood & adolescence

Part 1 – Introduction
KR311-2306CRV-V01

ANZBMS 2022 – Introducing a new era in the management of XLH

Full Video

The 10th Pediatric Endocrine Update 2022 : Highlights in Pediatric Endocrinology

New Insights in X-Linked Hypophosphatemic Rickets
KR175-2209CRV-W06

11th Asia Pacific Endocrine Society 2021 (APPES 2021) in Conjunction with the 42nd Malaysian Pediatric Association Annual Congress 2021

Phosphorus – The Forgotten Mineral for Strong Bone

X-Linked Hypophosphatemia – A new treatment paradigm

MY-CRV-23-00030 JUL2023

ANZBMS 2022 – Introducing a new era in the management of XLH

Part 3 – The safety and efficacy of CRYSVITA in adult patients
MY-CRV-23-00032

ANZBMS 2022 – Introducing a New Era in The Management of XLH

Part 2 – The safety and efficacy of Crysvita in Paediatrics
MY-CRV-23-00033

ANZBMS 2022 – Introducing a New Era in The Management of XLH

Part 1 – XLH – Looking back, Looking Forward
MY-CRV-23-00031

ANZBMS 2022 – Introducing a new era in the management of XLH

Full Video
MY-CRV-23-00034

APAC Consensus Recommendation on XLH – Multidisciplinary Management (Prof Craig F. Munns)

Full Video
SG-CRV-24-00001 JAN2024

APAC Consensus Recommendation on XLH – Transition of Care (Prof Rhee Yumie)

SG-NP-24-00001 JAN2024

ANZBMS 2023 Case Study – XLH – Burosumab initiation in adulthood (A.Prof Christian Girgis)

SG-CRV-24-00002 FEB2024

ANZBMS 2023 Case Study – XLH – Management considerations in adulthood (Prof Rory Clifton-Bligh)

SG-CRV-24-00003 FEB2024

Case sharing by Prof. Thomas O. Carpenter : XLH – Management challenges during childhood & adolescence

Full Video
MY-CRV-23-00022

Case sharing by Prof. Thomas O. Carpenter : XLH – Management challenges during childhood & adolescence

Part 5 – Questions & Answers
MY-CRV-23-00027

Case sharing by Prof. Thomas O. Carpenter : XLH – Management challenges during childhood & adolescence

Part 4 – Case Study of 9-year-old patient
MY-CRV-23-00025

Case sharing by Prof. Thomas O. Carpenter : XLH – Management challenges during childhood & adolescence

Part 3 – Case Study of 14-year-old patient
MY-CRV-23-00025

Cameron’s story

The next chapter
AU-CRV-23-00006 JUL2023

ANZBMS Case Study – Prof Rory Clifton-Bligh

ANZBMS Case Study – A.Prof Christian Girgis

ANZBMS 2023 Kyowa Kirin Australia Symposium – The Australian Crysvita XLH Experience

ANZBMS 2022 – Kyowa Kirin Symposium – Introducing a new era in the management of XLH

(Full Symposium incl. Q&A)

ANZBMS 2022 – Kyowa Kirin Symposium – Part 1

XLH – Looking back, looking forward

ANZBMS 2022 – Kyowa Kirin Symposium – Part 2

The safety and efficacy of CRYSVITA® (burosumab) in paediatrics

ANZBMS 2022 – Kyowa Kirin Symposium – Part 3

The safety and efficacy of CRYSVITA® (burosumab) in adults

An update on X-Linked Hypophosphatemia in Children and Adolescents (Prof Zulf Mughal)

SG-CRV-23-00025 OCT2023

X-Linked Hypophosphatemia – A new treatment paradigm

SG-CRV-23-00022 OCT2023

Case sharing by Prof. Thomas O. Carpenter : XLH – Management challenges during childhood & adolescence

(Full Video)

New Era of Management of X-Linked Hypophosphatemia

A New Era in Management of XLH

ANZBMS22

(Full video) Introducing a new era in the management of XLH
SG-CRV-23-00007 JUL2023

Cameron’s story

The next chapter
SG-CRV-23-00001 APR2023

The 10th Pediatric Endocrine Update 2022 : Highlights in Pediatric Endocrinology

New Insights in X-Linked Hypophosphatemic Rickets
SG-CRV-22-00013 AUG2022

11th Asia Pacific Endocrine Society 2021 (APPES 2021) in Conjunction with the 42nd Malaysian Pediatric Association Annual Congress 2021

Phosphorus – The Forgotten Mineral for Strong Bone
SG-CRV-22-00011 JUN2022

Expert Opinion Video – XLH & CRYSVITA® (burosumab)

CME Dinner Talk – Beyond Hypophosphatemic Rickets

MY-CRV-23-00042

Case sharing by Prof. Thomas O. Carpenter : XLH – Management challenges during childhood & adolescence

Part 2 – Case Study of 12-month-old patient
MY-CRV-23-00024

Cameron’s story

Part 2: The next chapter
MY-CRV-23-00016

Clinical Questions on XLH and Burosumab (Prof Thomas O. Carpenter)

MY-CRV-23-00023 SEP2023

Case sharing by Prof. Thomas O. Carpenter : XLH – Management challenges during childhood & adolescence

Part 1 – Introduction
MY-CRV-23-00011

New Era of Management of X-Linked Hypophosphatemia

A New Era in Management of XLH
MY-CRV-23-00015

The 10th Pediatric Endocrine Update 2022 : Highlights in Pediatric Endocrinology

New Insights in X-Linked Hypophosphatemic Rickets
MY-CRV-23-00014

11th Asia Pacific Endocrine Society 2021 (APPES 2021) in Conjunction with the 42nd Malaysian Pediatric Association Annual Congress 2021

Phosphorus – The Forgotten Mineral for Strong Bone
MY-CRV-23-00013

11th Asia Pacific Endocrine Society 2021 (APPES 2021) in Conjunction with the 42nd Malaysian Pediatric Association Annual Congress 2021

Phosphorus – The Forgotten Mineral for Strong Bone
HK-CRV-23-00013

The 10th Pediatric Endocrine Update 2022 : Highlights in Pediatric Endocrinology

New Insights in X-Linked Hypophosphatemic Rickets
HK-CRV-23-00014

New Era of Management of X-Linked Hypophosphatemia

A New Era in Management of XLH
HK-CRV-23-00015

Case sharing by Prof. Thomas O. Carpenter : XLH – Management challenges during childhood & adolescence

Part 1 – Introduction

Cameron’s story

The next chapter
SG-CRV-23-00001

Clinical Questions on XLH and Burosumab (Prof Thomas O. Carpenter)

(Full Video)

X-Linked Hypophosphatemia

Management Challenges During Childhood and Adolescence (Part 1)
HK-CRV-23-00016

ANZBMS 2023 – The Australian Crysvita XLH Experience

SG-CRV-23-00027 DEC2023

An update on X-Linked Hypophosphatemia in Children and Adolescents (Prof Zulf Mughal)

SG-CRV-23-00026 OCT2023

An update on X-Linked Hypophosphatemia in Children and Adolescents (Prof Zulf Mughal)

SG-CRV-23-00025 OCT2023

Key Clinical Questions about the diagnosis / treatment for XLH and Burosumab (Prof Craig F. Munns)

(Full Video)
SG-CRV-23-00019 OCT2023

X-Linked Hypophosphatemia – A new treatment paradigm

SG-CRV-23-00022 OCT2023

ANZBMS 2022 – Introducing a new era in the management of XLH

Full Video
SG-CRV-23-00007 JUL2023

Case sharing by Prof. Thomas O. Carpenter : XLH – Management challenges during childhood & adolescence

(Full Video)

Cameron’s story

The next chapter
SG-CRV-23-00001 APR2023

Clinical Questions on XLH and Burosumab (Prof Thomas O. Carpenter)

(Full Video)

11th Asia Pacific Endocrine Society 2021 (APPES 2021) in Conjunction with the 42nd Malaysian Pediatric Association Annual Congress 2021

Phosphorus – The Forgotten Mineral for Strong Bone
SG-CRV-22-00011 JUN2022

The 10th Pediatric Endocrine Update 2022 : Highlights in Pediatric Endocrinology

New Insights in X-Linked Hypophosphatemic Rickets
SG-CRV-22-00013 AUG2022

Key Clinical Questions about the diagnosis / treatment for XLH (Prof Craig F. Munns)

(Part 1) Diagnosis/Treatment of XLH
SG-CRV-23-00020 OCT2023

Key Clinical Questions about the diagnosis / treatment for XLH (Prof Craig F. Munns)

(Part 2) Burosumab
SG-CRV-23-00021 OCT2023

Q20 – Some patients may need to switch off from Burosumab back to conventional therapy. How would you manage such patients, and when should patients restart conventional therapy?

Q19 – What considerations should clinicians take into account with regards to Covid-19 vaccinations in patients on Burosumab?

Q18 – What are the key considerations when treating patients with XLH?

Q17 – What is your experience in transition of care from pediatrics to adults in XLH setting? What does good look like in transition of care?

Q16 – What is your experience with regards to growth rates in patients taking Burosumab? Has there been cases when growth rates became slower after taking Burosumab?

Q14 – How do you manage low serum Vitamin D levels in patients on Burosumab?

Q9 – How do you manage side effects such as fever and headaches in patients receiving Burosumab?

Q7 – What is your experience on dental abscess in patients receiving Burosumab? How do you manage dental abscess in patients on Burosumab?

Q6 – What is your experience on the efficacy of Burosumab in children with XLH?

Q5 – For which XLH patients should Burosumab be considered?

Q4 – How important is Burosumab in the treatment of XLH?

Q2 – What specialists or multidisciplinary care team should be involved in the care of XLH patients? And how?

Q1 – Why is it important to restore and maintain life-long phosphate homeostasis in patients with X-Linked Hypophosphatemia (XLH)?

Case sharing by Prof. Thomas O. Carpenter : XLH – Management challenges during childhood & adolescence

Part 1 – Introduction

Case sharing by Prof. Thomas O. Carpenter : XLH – Management challenges during childhood & adolescence

Part 2 – Case Study of 12-month-old patient

Case sharing by Prof. Thomas O. Carpenter : XLH – Management challenges during childhood & adolescence

Part 3 – Case Study of 14-year-old patient

Case sharing by Prof. Thomas O. Carpenter : XLH – Management challenges during childhood & adolescence

Part 4 – Case Study of 9-year-old patient
AP-CRV-23-00009 JAN2023

Case sharing by Prof. Thomas O. Carpenter : XLH – Management challenges during childhood & adolescence

Part 5 – Questions & Answers
AP-CRV-23-00009 JAN2023

ANZBMS 2022 – Introducing a New Era in The Management of XLH

Part 3 – The safety and efficacy of CRYSVITA in adult patients
SG-CRV-23-00006 MAY2023

ANZBMS 2022 – Introducing a New Era in The Management of XLH

Part 2 – The safety and efficacy of Crysvita in Paediatrics
SG-CRV-23-00005 MAY2023

ANZBMS 2022 – Introducing a New Era in The Management of XLH

Part 1 – XLH – Looking back, Looking Forward
SG-CRV-23-00004 JUN2023